Introduction
The process of tumorigenesis, previously thought to stem primarily from genetic changes within transformed cells, is now known to also depend on extracellular signals from noncancerous cells present in the tumor microenvironment (TME) (1) . Among the normal cells that contribute to the TME are bone marrow-derived myeloid cells whose function and contribution to neoplastic growth has been best understood (2) . Recently, there has been increased evidence that bone marrow-derived mesenchymal cells also contribute to tumorigenesis and metastasis, but their role has been less well characterized (3, 4) . Within the bone marrow microenvironment, BMMSC and osteoblasts provide a supportive niche for homing of hematopoietic stem cells (HSC) and tumor cells which promotes quiescence and survival (5) .
These cells also serve to generate the various connective tissue lineages (adipocyte, osteoblast, chondrocyte, myocyte, neuron, fibroblast) found in the marrow and in distal organs, and are actively recruited to sites of injury, inflammation and neoplastic transformation where it has been suggested they give rise to fibroblasts (6) .
The kinetics of BMMSC recruitment from the marrow niche, as well as their distribution in primary tumors, are still poorly characterized. BMMSC display a chemotactic response to chemokines, growth factors, and extracellular matrix (ECM) proteases produced by tumor cells, which mimics the activity of inflammatory HSC and is mechanistically indistinguishable from the generalized wound healing response (7) . Though BMMSC exhibit potent effects even in small numbers, studies of tumor-recruited BMMSC suggest that their migration is inefficient and difficult to quantify in vivo (8) .
However, once recruited to tumor sites BMMSC differentiate into myofibroblasts (9) as well as tumor-associated fibroblasts (TAF), which produce mitogenic and angiogenic factors and display potent ECM remodeling capabilities (10) . Cytokines secreted by BMMSC are also known to modulate immune responses within the TME, creating immunosuppressive effects which drive tumor progression (11) . Concordantly, introduction of BMMSC into tumor bearing mice by intravenous injection or co-injection shows a net positive effect on tumor growth in a majority of studies (12, 13) . However, anti-tumorigenic effects, driven by increased caspase-3 and PARP-1 cleavage, have also been reported (14) . Most published work on the MSC-tumor interaction has focused on proliferative, angiogenic and immunoregulatory effects. Previous studies conducted in our laboratory have identified a pro-survival effect of human BMMSC on metastatic human neuroblastoma cells in the bone marrow microenvironment that promotes drug resistance (15, 16) . This observation provides the basis for our present examination of a novel role of these mesenchymal cells and their derivatives within primary tumors, rather than the bone marrow.
We hypothesized that circulating BMMSC are incorporated into primary tumor sites and protect tumor cells from spontaneous and therapy-induced apoptosis via the production of soluble factors, similar to the role of native BMMSC in promoting metastatic tumor cell survival in the bone marrow microenvironment.
Material and Methods

Cells
The murine cell lines 4T1 mammary carcinoma, LL/2 Lewis lung carcinoma and NIH3T3 fibroblasts were purchased from ATCC (American Type Culture Collection), which uses short terminal repeat (STR) profiling for characterization. All cells were passaged for less than 6 months after resuscitation. Cells were cultured in DMEM (Dulbecco's Modified Eagle Medium) or RPMI-1640 (4T1 cells) containing 10% fetal calf serum (FCS) and supplemented with 1% penicillin-streptomycin. Normal murine fibroblasts were obtained from skin samples from [6] [7] [8] week-old Balb/cJ mice (Jackson Laboratories). Four mm 2 fragments were placed in a 6 cm culture dish (3 sections per dish) and covered with 100 µL DMEM containing 10% FCS. Skin fragments were removed from the culture dish when adherent colonies of growing cells could be identified. These colonies of fibroblast cells were allowed to expand to 70% confluence before being harvested by trypsinization and transferred to 10 cm culture dishes for routine passaging.
Murine BMMSC were obtained from 6-8 week-old Balb/cJ mice using a protocol adapted from Kirshner, et al. (17) . In brief, animals were sacrificed and femurs, iliac bones and tibias were used. The extremities of each bone were removed with scissors and the marrow cavity was flushed a first time with phosphate buffered saline (PBS) using a 27-gauge needle to remove non-adherent hematopoietic cells, and the material was discarded. Each bone was then flushed a second time with PBS, using the needle to simultaneously scrape the endosteal surface of the marrow cavity. Flow through material from the second flush was collected, subjected to hemolysis and spun to remove debris. Pooled bone marrow cells from each animal were plated in BMMSC culture medium (Iscove's Modified Dulbecco Medium IMDM) containing 15% FCS and 15% denatured horse serum (DHS) supplemented with hydrocortisone (10 -6 mol/L), 2-mercaptoethanol (10 -4 mol/L), and 1% penicillin-streptomycin in one well on a 12-well culture dish coated with collagen I and fibronectin, both at 5 µg/cm 2 . Bone marrow cells were cultured for 24 hours and non-adherent cells removed by gentle washes two times. Adherent cells were grown for 3-6 weeks to allow the development of a confluent stromal monolayer and then harvested for routine passaging in regular plastic tissue culture dishes.
Reagents: Anti-mouse CD34-PE, CD45-PerCP, CD31-PE, VEGFR2-PE, and CD44-FITC 6 were purchased from BD (Becton Dickinson). Anti-mouse E-Cadherin antibody was purchased from R&D Systems. Paclitaxel was purchased from Sigma, and doxorubicin from GensiaSicor.
Fluorescent cell labeling
BMMSC were labeled for detection by fluorescence microscopy using the PKH26 Red Fluorescent Cell Linker Kit (Sigma). Briefly, 10 7 BMMSC were rinsed with PBS, loosely pelleted, and suspended in 1 mL PBS for staining with 8 µL red fluorescent dye. Cells were stained for 90 seconds, followed by treatment with 2 mL BMMSC culture medium and an additional 60 seconds of staining. Cells were pelleted and rinsed three times with culture medium, with a fresh tube used for each rinse. Cells were rinsed two times with PBS, plated on a 10 cm dish in culture medium, incubated for 24 hours at 37°C, and harvested for use.
Flow cytometry
BMMSC were harvested with PBS-based cell dissociation buffer (Gibco) and suspended in PBS containing 5% FCS (v/v) and 0.1% sodium azide (w/v). Analysis was performed using a FACS Caliber flow cytometer and data were analyzed using CellQuestPro software.
Osteocyte/adipocyte staining
For analysis of spontaneous differentiation, BMMSC were plated in 48-well dishes, allowed to expand for 14 days, and fixed in 4% paraformaldehyde (PFA) prior to staining for either alkaline phosphatase activity (AP), using a detection kit (Millipore), or for triglyceride deposits, using oil red O (ORO; Sigma). For directed osteocyte differentiation, BMMSC were treated with osteocyte differentiation medium (StemPro osteocyte/chondrocyte differentiation medium from Gibco) for 21 days, fixed in 4% PFA (w/v), and stained with alizarin red (Sigma) to detect calcium deposits. For directed adipocyte differentiation, BMMSC were plated in 12-well dishes treated with adipocyte maintenance medium (DMEM 15% FCS, 20 mM HEPES, 1 mM sodium pyruvate, 2 mM glutamase-1, and 1% penicillin-streptomycin) up to 100% confluency, switched to adipocyte induction medium for 2 days (150 mM insulin, 125 mM dexamethasone, 500 mM IBMX), fixed in 4% PFA, and stained with ORO.
BMMSC conditioned medium.
Conditioned medium (CM) from BMMSC was obtained from BMMSC plated in 10 cm dishes and grown to a confluent monolayer. Cells were rinsed with PBS and treated with two changes of BMMSC culture medium containing 0.5% FCS (v/v) and 0.5% DHS (v/v) (1% total serum), 0.25% FCS (v/v) and 0.25% DHS (v/v) (0.5% total serum), or no serum for 30 minutes each. Medium was replaced with 10 mL culture medium containing 0.5% total serum, 1% total serum, or no serum. After 3-4 days exposure to BMMSC, the CM was collected and spun to remove cellular debris and stored at 4°C prior to testing. CM was also generated from NIH3T3 cells and normal murine fibroblasts by the same method.
Cell proliferation and apoptosis assays
For 2D proliferation assays, tumor cells were cultured in 6-well plates at 5x10 4 per well in the presence of CM from MSC, NIH3T3, skin fibroblasts or IMDM, all containing 1% serum (v/v). Cells were harvested by trypsinization and counted in a hemocytometer. For 2D transwell proliferation assays, 4T1 tumor cells were cultured in 6-well plates at 5x10 caspase-9, and caspase-8 activity was determined using the appropriate ApoTarget colorimetric protease assay kit (Life Technologies) on aliquots containing 50 µg protein.
Drug resistance assay
Tumor cells were plated in opaque white 96-well culture plates at 1x10 reporter activity was measured via GloMax Multi Detection System (Promega), using Instinct software (Promega). For determination of caspase-3/7 activity, tumor cells were treated with paclitaxel or doxorubicin for 24 hours in the presence of 1% serum (LL/2) or 0.5% serum (4T1) CM or BMMSC culture medium. Caspase-Glo 3/7 reagent (Promega) was then added to each well at a 1:1 ratio with the cell medium, and luminescent reporter activity was measured as above described. For apoptosis induction, 4T1 cells were cultured in 6-well plates at 3x10 
Transwell migration assay
For transwell migration studies, 8x10 3 BMMSC were plated in 24-well, 8.0 μm pore size transwell inserts and exposed to serum-free tumor cell CM or control medium added to the lower chamber of the transwell dish. After migration, transwell inserts were removed and the upper side of the filter was swabbed to remove non-migratory cells. Transwell filters were then fixed/stained with the Hema3 Stat Pack (Protocol) as per the manufacturer's instructions. Filters were cut free and mounted on slides in a drop of immersion oil for microscopic examination.
BMMSC iron labeling
BMMSC were grown in 10 cm dishes to form a low-density monolayer (1-2x10 with 2U/mL heparin (Sigma). Within 15 seconds, 60 µg/mL protamine sulfate (APP Pharmaceuticals) was added to medium, with gentle agitation of the dish. Within another 15 seconds, 100 µg/mL Feraheme (AMAG Pharmaceuticals) was added to medium, with simultaneous agitation of the dish. Cells were incubated for 2 hours at 37ºC and 5% CO2, followed by addition of 6.5 mL BMMSC culture medium. After 24 hours, cells were rinsed with PBS, followed by a second rinse with PBS containing 10U/mL heparin, followed by a third rinse with PBS. Cells were harvested by trypsinization for use in vivo.
Animal experiments
Studies in mice were performed under a protocol approved by the Institutional Animal Care apoptotic cells using the Cell Death Detection Kit (Roche), as previously reported (18) .
Statistical analysis
Comparisons between two groups were performed by unpaired Student t test with unequal variances assumed, while multiple group comparisons were performed by 2-way ANOVA or linear regression analysis. T tests and ANOVA were performed using Excel (Microsoft), and linear regression analysis was performed using Stata 11 software (StataCorp). Two sided p values are reported.
Results
BMMSC characterization
Murine MSC harvested from the bone marrow and expanded in vitro were tested for their stem cell potential by a combination of surface marker staining and functional studies (Table 1 ; Fig. 1 ). FACS analysis of BMMSC revealed positive staining for CD44, a surface marker that is highly enriched on mesenchymal cells at both early (<10) and late (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) passages (19) ( Table   1 ). The cells were negative for the endothelial markers CD31 and VEGFR2 at early and late passages, along with the myeloid marker CD45. Weak positive staining for the hematopoietic marker CD34 was observed at early passages, potentially due to the presence of some myeloid cells that were not eliminated in the washing procedure. Late passage BMMSC were negative for CD34, which parallels the loss of contaminating cell types over subsequent passages (Fig.   1A ). The tested cells thus displayed characteristic BMMSC markers by cell surface phenotype.
To establish whether these cells also retained their pluripotent function, they were cultured
for an extended period and tested for spontaneous generation of both adipocytes and osteoblasts. Analysis of a single BMMSC culture over multiple passages showed relatively stable levels of adipogenesis (2-8%), while early osteoblastic differentiation potential (around 2%) decreased at around passage 8 (Fig. 1B) . Late passage BMMSC were able to generate mature osteocytes, characterized by alizarin red-positive calcium deposits, when cultured in osteoblast induction medium (Fig. 1C) , and cultures of BMMSC treated with adipogenesis induction medium showed an increased percentage of ORO-positive cells versus controls, which generated smaller numbers of more mature adipocytes (Fig. 1D) . The observed spontaneous and inducible differentiation of osteoblasts and adipocytes in these experiments confirmed the identity of the tested cells as BMMSC.
BMMSC enhance tumor cell expansion
In order to determine the effect of BMMSC on tumor cell expansion, 4T1 murine mammary adenocarcinoma cells were first grown in 3D cultures of Matrigel in the presence of BMMSC, NIH3T3 cells, or normal mouse fibroblasts plated in transwells. This experiment revealed that BMMSC stimulated the formation of a number (46 ± 12 per well) of tumorspheres whereas 4T1 cells failed to form tumorspheres in the presence of NIH3T3, fibroblasts, or controls (p < 0.02) ( Fig. 2A) . This stimulatory effect on tumorspheres required the presence (although not the contact) of BMMSC because Matrigel-embedded 4T1 cells grown in the presence of serum-free CM from BMMSC, NIH3T3, fibroblasts or serum-free control medium did not form any discernible tumorspheres (data not shown). Using 2D cultures of 4T1 grown in the presence of 1% serum CM from BMMSC, NIH3T3 and fibroblasts, we then observed a 1.5-fold increase in cell numbers in cultures exposed to BMMSC CM but not to CM from NIH3T3 or fibroblasts (p = <0.001 by ANOVA) (Fig. 2B) . A similar increase in cell number in the presence of BMMSC but not NIH3T3 or skin fibroblasts was observed when 4T1 cells were co-cultured in transwells (p = <0.001 by ANOVA) (Fig. 2B) . Similarly, LL/2 cells exposed to 1% serum CM from BMMSC showed a significantly higher (2 fold) increase in the number of viable cells (Supplementary Fig. S1 ). The data thus indicated that BMMSC increased the viability of tumor cells by a mechanism that did not require direct cell-cell contact and was primarily mediated by soluble factors present in the CM. To determine if this increase in tumor cell expansion stemmed from enhanced proliferative potential vs. changes in spontaneous apoptosis, 4T1 cells cultured in the presence or absence of BMMSC CM were examined for proliferation by cell cycle analysis. The data revealed that 4T1 cells grown in the presence of 1% serum CM from BMMSC showed no significant increase in the percentage of cells in S-phase or G2/M-phase at 2 days, but a significant decrease in the percentage of cells in S-phase and G2/M-phase at 4 days, suggesting in fact an inhibitory effect on proliferation ( Supplementary Fig. S2A ). Using BrdU labeling, we did not find any significant difference in the percentage of cells in G2 phase in the presence of BMMSC CM versus regular medium ( Supplementary Fig. S2B ). These data thus suggested that the increase in viability observed when tumor cells were cultured in the presence of BMMSC CM was not due to a positive effect on proliferation.
BMMSC protect tumor cells from spontaneous apoptosis
We therefore explored whether BMMSC could affect tumor cell survival. 4T1 grown in 1% serum CM or control medium for 3-5 days were stained with Annexin V-FITC and PI and examined by flow cytometry (Fig. 2C) Fig. S3A ). Consistent with a protective effect of BMMSC CM on apoptosis, an analysis of cell lysates from 4T1 cells indicated a statistically significant decrease in the level of caspase-3 activity in cells exposed to CM from BMMSC for 5 days, compared to controls (44.5% of control) (Fig. 2D) . Similar data were observed with LL/2 cells (Supplementary Fig.   S3B ). The data thus suggest that the observed increase in viability in tumor cells cultured in the presence of BMMSC was primarily the result of a protective effect against apoptosis induced by serum starving. In order to determine if this protective effect stemmed from a suppression of intrinsic or extrinsic apoptotic signaling, we examined the effect of CM from BMMSC on caspase-9 and -8 activity. These data revealed a statistically significant decrease in caspase-9 activity (44.2% of control) and a non-significant inhibition of caspase-8 activity (25% of control) in 4T1 cells cultured in the presence of CM from BMMSC at day 5, consistent with a primary protective effect on intrinsic apoptosis (Fig. 2D) . The data thus indicated that CM of BMMSC increased the viability of tumor cells primarily by having a protective effect on intrinsic apoptosis.
BMMSC protect tumor cells from drug-induced apoptosis
We then asked whether BMMSC would also protect tumor cells from drug-induced apoptosis. For these experiments, 4T1 and LL/2 cells were exposed to apoptosis-inducing drugs 
in the presence or absence of CM containing 1% total serum (LL/2) or 0.5% total serum (4T1).
4T1 cells cultured in the presence of BMMSC-derived CM and treated with paclitaxel or doxorubicin (concentrations ranging from 0.00001 to 100 µmol/L) showed a significantly greater survival than control cells cultured in regular medium at therapeutic concentrations (Fig. 3A) , as confirmed by linear regression analysis (p ≤ 0.001). Similarly, LL/2 cells treated with paclitaxel or doxorubicin at therapeutic concentrations showed a significantly greater survival when cultured in the presence of BMMSC-derived CM than in the presence of regular medium ( 
induced apoptosis but also from drug-induced apoptosis.
BMMSC suppress drug-induced apoptosis in vivo
We then asked whether exogenous BMMSC would protect tumors from chemotherapy- 
BMMSC migrate toward tumor-derived products in vitro
We then investigated whether BMMSC would be attracted by primary tumors. We initially explored this possibility by testing the effect of tumor cell-derived CM on BMMSC migration in vitro in a transwell migration assay. This experiment indicated a robust migration of BMMSC upon exposure to serum-free 4T1 and LL/2 CM for 2 days (Fig. 6A) . Further experiments utilizing serum-free 4T1 and LL/2 CM also demonstrated significant BMMSC recruitment after (22) . Our examination of adipogenic and osteogenic differentiation was sufficient to confirm the mesenchymal origin of these BMMSC without conducting a full characterization of their ability to generate other lineages (chondrocyte, muscle, etc.). Additionally, the surface marker profile for these primary cells, which were positive for CD44 and negative for CD34, CD45, CD31, and VEGFR2, confirmed them to be of mesenchymal origin, as opposed to hematopoietic or endothelial origin, without a full characterization of their mesenchymal marker expression (19) . As mentioned previously, the low level of CD34 found in early passage BMMSC may indicate the presence of non-adherent myeloid cells or adherent fibrocytes, which express hematopoietic markers but exhibit a mesenchymal-like phenotype and contractile properties (23) . Weak CD34 expression may also represent a transient production of this marker by BMMSC (24) . Given the phenotypic and functional characteristics of our primary cells, they are appropriately referred to as mesenchymal stromal cells (25) .
Our current study adds to the body of literature on the effect of BMMSC on tumor cell growth by specifically pointing to an effect on survival rather than on proliferation. The growth enhancement effects of BMMSC reported typically involve a stimulation of tumor cell proliferation, as demonstrated for example in human and rat osteosarcoma (12, 13) . Human colorectal carcinoma xenografts also show increased proliferation in the presence of BMMSC in multiple studies (26, 27) . Additional growth stimulatory effects are reported in mammospheres Polarization of BMMSC into an anti or pro-tumorigenic function, similar to the one observed in T cells and macrophages, may also explain the discrepancy in BMMSC functions (34) .
The novelty of the data presented in this manuscript relates to the observation that the positive effect of BMMSC on tumor cell viability was not due to an effect on proliferation but rather on survival, an effect that has not been much explored so far. Several published studies have in fact reported a pro-apoptotic effect of BMMSC on tumor cells. For example, intravenous injection of MSC has been shown to increase PARP-1 and caspase-3 cleavage in mammary carcinoma xenografts (35) , and murine hepatoma and lymphoma cells were reported to increase the production of caspase-3 and p21 proteins when exposed to BMMSC in vitro and in vivo (14) . Additionally, direct injection of BMMSC in rat gliomas increased tumor cell expression of pro-apoptotic caspase-3 and Bax while downregulating anti-apoptotic Bcl-2 (36) .
The disparity between these findings and our own observation of BMMSC-mediated suppression of tumor cell apoptosis may stem from our use of serum depletion and drug-induced cell death models. It should be pointed out that these previous studies have examined apoptosis of tumor cells exposed to MSC under unstressed conditions, suggesting that MSC can increase baseline Importantly, we clearly demonstrate that the protective effect of BMMSC on tumor cells is specific, as it was not observed with either NIH3T3 cells or normal mouse skin fibroblasts which were used as control in multiple experiments. It thus underlines a property of MSC that is not shared with other cells of mesenchymal nature but does not eliminate a similar property in nonmesenchymal cells such as endothelial cells or myeloid cells. In fact, a protective effect against chemotherapy-induced apoptosis has been reported for tumor-associated macrophages (42) .
The observed protective effect of BMMSC on primary tumor cell survival was contactindependent, as has been found in previous studies of metastatic tumor cells in the bone marrow.
Production of GDF15 by bone marrow-resident BMMSC protects multiple myeloma cells from melphalan, bortezomib and lenalidomide (43) , and several laboratories including ours have identified a chemoprotective effect of BMMSC on tumor cells driven by Il-6, which increases in a STAT3-dependent manner, the expression of anti-apoptotic Bcl2, BclXl, survivin and XIAP, as well as multidrug resistance proteins MDR and MRP (44) (45) (46) (47) . The identity of the protective factor(s) involved in our observed suppression of tumor cell apoptosis is currently investigated by our laboratory and preliminary data points to soluble proteins. It should be noted that other signaling molecules besides proteins could also be involved in this protective effect, as fatty acids released by BMMSC in response to platinum-based therapies have been shown to protect murine colon carcinoma and Lewis lung carcinoma tumors from platinum-induced cytotoxicity (48) . 
may be involved since BMMSC have been shown to exhibit migration in response to a large variety of growth factors and cytokines (50, 51) .
In summary, in this manuscript we provide data identifying BMMSC as an important mediator of tumor cell survival and drug resistance, and evidence that BMMSC could exert this function not only in the bone marrow as previously assumed but also in the primary tumor. 
